United States News Todas as matérias

AbbVie (NYSE:ABBV) shares are in focus after the biopharmaceutical giant released positive topline results for its investigational obesity treatment, ABBV-295.

Sharplink (NASDAQ:SBET) reported full-year 2025 financial and operating results on Monday, marking the completion of its strategic transformation into one of the world's largest corporate holders of Ether (ETH).

Jet.AI (NASDAQ:JTAI) transitioned to profitability in 2025 as the company aggressively shifted its focus from private aviation services toward hyperscale AI data center development.

YY Group Holding (NASDAQ:YYGH), a Singapore-based provider of on-demand staffing and integrated facility management services, on Monday released preliminary, unaudited financial results for the full year ended December 31, 2025, estimating revenue in the range of $57 million to $58 million, representing year-over-year growth of approximately 38.7% to 41.1%.

Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) reported a fourth-quarter loss that was narrower than analysts anticipated, bolstered by a significant cash injection and clinical progress in its high-priority obesity and oncology programs.

Nayax (NASDAQ:NYAX) reported fourth-quarter earnings on Monday that cleared Wall Street’s profitability hurdles, even as revenue narrowly missed consensus estimates.

ZIM Integrated Shipping Services (NYSE:ZIM) reported fourth-quarter earnings on Monday that signaled a recovery in the global container market, bolstered by a strategic shift toward more fuel-efficient vessels.

W&T Offshore (NYSE:WTI) reported a fourth-quarter loss on Monday, reflecting the impact of a volatile commodity price environment even as the company successfully boosted output in the Gulf of Mexico.

FuelCell Energy (NASDAQ:FCEL) shares traded lower on Monday after the company’s first-quarter revenue failed to meet market expectations, highlighting the uneven pace of the global energy transition.

Editas Medicine (NASDAQ:EDIT) reported fourth-quarter results on Monday that significantly outpaced Wall Street projections, fueled by higher collaboration revenue and a sharp reduction in operating expenses.

3D Systems (NYSE:DDD) reported a fourth-quarter loss that underscored the ongoing volatility in the industrial manufacturing sector, even as the company saw a double-digit jump in sequential sales.

Dianthus Therapeutics (NASDAQ:DNTH) is accelerating the development of its lead immunology candidate after an interim analysis of its Phase 3 CAPTIVATE trial yielded positive results earlier than anticipated.

enCore Energy (NASDAQ:EU) reported a surge in operational output for fiscal year 2025 on Monday, as the South Texas-based producer successfully ramped up its Alta Mesa and Rosita projects to capitalize on a tightening global uranium market.

ACCO Brands reported its fourth-quarter and full-year 2025 results on Monday, highlighting a resilient bottom line and expansion in gaming accessories despite a broader slowdown in global demand for traditional office products.

Bristol Myers Squibb reached a major milestone in its next-generation protein degradation program on Monday, reporting that its oral CELMoD agent, mezigdomide, significantly extended the time patients lived without their cancer progressing in a pivotal Phase 3 study.

Pfizer announced positive topline results for its investigational trispecific antibody, tilrekimig, which demonstrated significant skin clearance in adults with moderate to severe eczema and paved the way for a pivotal Phase 3 study later this year.

Korn Ferry (NYSE:KFY) reported a strong third quarter for fiscal 2026, with fee revenue reaching $717.4 million as the global consulting firm successfully leveraged high-growth digital services and long-term contracts to offset broader economic shifts.

ARS Pharmaceuticals reported its 2025 financial results on Monday, highlighting the successful U.S. commercial launch of neffy, the first needle-free epinephrine nasal spray, which now anchors the company’s path toward cash-flow break-even.

Heritage Insurance Holdings (NYSE:HRTG) capped a landmark fiscal year with a surge in fourth-quarter net income, as a dramatically improved combined ratio and strategic geographic expansion propelled book value to record heights.

Signet Jewelers (NYSE:SIG) reported preliminary full-year 2026 results on Monday, revealing that a shift toward higher-end merchandise successfully bolstered annual growth despite a slight cooling in fourth-quarter store traffic.

BETA Technologies reported a significant jump in full-year 2025 revenue following its market debut, as the electric aerospace pioneer scales its charging infrastructure and begins high-volume deliveries of its proprietary propulsion systems.

IDEAYA Biosciences reached a key clinical milestone on Monday, dosing the first patient in its Phase 1 trial for IDE892, a potential best-in-class PRMT5 inhibitor designed to target MTAP-deleted solid tumors.

Woodward signed a definitive agreement on Monday to acquire Florida-based Valve Research & Manufacturing Company, a move designed to deepen the industrial giant’s component density on both current and future-generation aircraft platforms.

HUTCHMED initiated a full market recall of the oncology drug Tazverik across Greater China on Monday, following a global withdrawal by partner Ipsen due to emerging safety data linking the therapy to secondary blood cancers.